Edition:
United Kingdom

DBV Technologies SA (DBVT.OQ)

DBVT.OQ on NASDAQ Stock Exchange Global Select Market

21.93USD
15 Dec 2017
Change (% chg)

$0.23 (+1.06%)
Prev Close
$21.70
Open
$21.47
Day's High
$21.97
Day's Low
$21.31
Volume
79,852
Avg. Vol
131,678
52-wk High
$50.40
52-wk Low
$20.59

Latest Key Developments (Source: Significant Developments)

DBV Technologies says Viaskin Peanut study demonstrates good tolerance and safety of product
Monday, 20 Nov 2017 

Nov 20 (Reuters) - DBV TECHNOLOGIES SA ::SAYS STUDY DEMONSTRATES GOOD TOLERANCE AND SAFETY OF PRODUCT, COMPARABLE TO PREVIOUS STUDIES.FIST PERIOD OF STUDY COMPARED SAFETY OF TREATMENT WITH VIASKIN PEANUT 250 ΜG TO PLACEBO FOR 6 MTHS.RESULTS WILL SERVE AS A BASIS FOR PLANNED DISCUSSIONS WITH REGULATORY AUTHORITIES.SOME SERIOUS ADVERSE EVENTS WERE OBSERVED IN THE TRIAL.PATIENTS WHO COMPLETED FIRST PART OF STUDY WILL RECEIVE ACTIVE TREATMENT FOR 36 MTHS.  Full Article

DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - DBV TECHNOLOGIES SA ::‍ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT​.‍PRIMARY ENDPOINT OF PHASE IIB STUDY WAS MET AFTER 12 MONTHS OF TREATMENT​.‍LONG-TERM EXTENSION DATA SHOWED TREATMENT BENEFIT INCREASES OVER TIME​.‍ONGOING VIASKIN PEANUT PHASE III PROGRAM INCLUDES THREE GLOBAL STUDIES IN CHILDREN​.  Full Article

DBV Technologies reports at Sept. 30 cash position of 170.5 million euros
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - DBV TECHNOLOGIES SA ::CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 ‍​.  Full Article

DBV Technologies ‍cash position of 170.5 million euros as of September 30​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - DBV TECHNOLOGIES SA ::‍CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2017, WERE EUR 170.5 MILLION, COMPARED TO EUR 256.5 MILLION AS OF DECEMBER 31, 2016.​.  Full Article

DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Dbv Technologies Sa :DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age‍​.DBV Technologies - topline results show statistically significant response with a favorable tolerability profile.DBV Technologies - primary endpoint did not reach 15% lower bound of CI that was proposed in study’s statistical analysis plan‍​.DBV Technologies - DBV will continue ongoing discussions with FDA, and plans to proceed with the BLA preparation process.  Full Article

DBV Technologies completes blinded period in REALISE study of Viaskin Peanut
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF BLINDED PERIOD IN REALISE STUDY OF VIASKIN PEANUT.‍97.5% OF PATIENTS CONTINUE TREATMENT IN OPEN-LABEL ARM OF REALISE STUDY​.‍PATIENTS WILL RECEIVE ACTIVE TREATMENT FOR A TOTAL OF 36 MONTHS​.‍COMPANY ANTICIPATES ANNOUNCING TOPLINE RESULTS FROM BLINDED PORTION OF REALISE TRIAL IN NOVEMBER 2017​.  Full Article

DBV Technologies announces expansion of clinical program for the treatment of peanut allergy
Tuesday, 2 Aug 2016 

DBV Technologies SA : Announced on Monday expansion of clinical program Viaskin Peanut for the treatment of peanut allergy .Topline results for trials are expected in the second half of 2017.  Full Article

DBV Technologies H1 net loss widens to 49.4 million euros
Thursday, 28 Jul 2016 

Dbv Technologies Sa : H1 net loss of 49.4 million euros ($54.66 million) versus loss of 14.5 million euros year ago . H1 cash position of 288.8 million euros versus 104.5 million euros year ago .H1 total income 4.8 million euros versus 3.2 million euros year ago‍​.  Full Article

DBV Technologies Sa files for stock shelf with U.S. SEC size undisclosed - SEC Filing
Wednesday, 27 Jul 2016 

DBV Technologies Sa :Says files for stock shelf with U.S. SEC; size undisclosed - SEC filing.  Full Article

Dbv Technologies appoints Lucia Septién as chief medical officer
Tuesday, 5 Jul 2016 

Dbv Technologies SA :Announced appointment of Lucia Septién, M.D., as chief medical officer.  Full Article

BRIEF-DBV Technologies says Viaskin Peanut study demonstrates good tolerance and safety of product

* SAYS STUDY DEMONSTRATES GOOD TOLERANCE AND SAFETY OF PRODUCT, COMPARABLE TO PREVIOUS STUDIES